The study is coordinated by Thierry de Baere (Gustave Roussy, Villejuif, France) and will evaluate the clinical performance and safety of the Epione device for the treatment of these tumours.
Epione is a robotic platform capable of assisting interventional radiologists in planning and performing minimally invasive procedures for the percutaneous ablation of tumours in the abdomen. Available in France and the USA, the Epione robot has already been used in procedures on more than 150 patients with liver or kidney cancer. With this study, Quantum Surgical aims to obtain an extension of its marketing authorisations in Europe and the USA with an indication extended to the treatment of lung tumours.
“This study sets a new milestone in the development of Quantum Surgical, and I am proud that it is being done in collaboration with Gustave Roussy, whose teams see the full potential of our technology. This is another step towards the dissemination of our innovation to other cancer patients”, said Bertin Nahum, president and co-founder of Quantum Surgical.